The Testosterone Replacement Product Liability Multidistrict Litigation (MDL) No. 2545 now includes a total of 1,358 cases, according to Court documents. This includes the transfer of a number of cases filed on or on behalf of men who allegedly suffered a heart attack, stroke, or other serious health problem while using a testosterone replacement therapy product.
The testosterone drug MDL was established in June 2014 when eight separate actions were transferred to the Northern Illinois District for pretrial proceedings. While these initial claims only included allegations of heart attack, stroke, and other health conditions linked to use of the testosterone drug Androgel, the MDL has now been expanded to include testosterone cases against a number of Low-T drugs, including:
Allegations of Claims
Court documents show that the testosterone lawsuits allege that patients suffered serious cardiovascular problems including:
- Deep vein thrombosis
- Heart attack
- Pulmonary embolism
The complaints also allege that the low testosterone drug makers hid these serious side effects and failed to warn patients and their doctors about potentially life threatening risks.
What is Testosterone?
Testosterone is a hormone produced primarily in the male testicles, and helps maintain:
- Bone density
- Fat distribution
- Muscle strength and mass
- Facial and body hair
- Red blood cell production
- Sex drive
- Sperm production
Testosterone levels typically peak during adolescence and early adulthood, and decline as men age – usually about one percent per year after age 30 or 40. According to the Mayo Clinic, it is important to determine if a low testosterone level in an older man is due to the decline of normal aging or if it is due to a disease known as hypogonadism. Although some believe that testosterone medications may help men feel younger and more vigorous as they age, testosterone therapy has various serious risks that should be discussed with a doctor.
The next scheduled court proceeding in the testosterone MDL is a case management conference scheduled for April, and presiding judge Matthew F. Kennelly has set a schedule to conclude all bellweather cases by April 2017. These bellweather cases are expected to set a precedent for all the other testosterone lawsuits.